HAT-P-9b: A Low Density Planet Transiting a Moderately Faint F star

We report the discovery of a planet transiting a moderately faint (V=12.3 mag) late F star, with an orbital period of 3.92289 +/- 0.00004 days. From the transit light curve and radial velocity measurements we determine that the radius of the planet is R_p = 1.40 +/- 0.06 R_Jup and that the mass is M_p = 0.78 +/- 0.09 M_Jup. The density of the new planet, rho = 0.35 +/- 0.06 g cm^{-3}, fits to the low-density tail of the currently known transiting planets. We find that the center of transit is at T_c = 2454417.9077 +/- 0.0003 (HJD), and the total transit duration is 0.143 +/- 0.004 days. The host star has M_s = 1.28 +/- 0.13 M_Sun and R_s = 1.32 +/- 0.07 R_Sun.Comment: Submitted to ApJ; V2: Replaced with accepted versio

Specific detection and quantitation of bovine IgG in bioreactor derived mouse mAb preparations

L

COVID-19 vaccinations: summary guidance for Cancer patients in 28Languages: breaking barriers to Cancer patient Information

Background: Covid-19 vaccination has started in the majority of the countries at the global level. Cancer patients are at high risk for infection, serious illness, and death from COVID-19 and need vaccination guidance and support. Guidance availability in the English language only is a major limit for recommendations' delivery and their application in the world's population and generates information inequalities across the different populations. Methods: Most of the available COVID-19 vaccination guidance for cancer patients was screened and scrutinized by the European Cancer Patients Coalition (ECPC) and an international oncology panel of 52 physicians from 33 countries. Results: A summary guidance was developed and provided in 28 languages in order to reach more than 70 percent of the global population. Conclusion: Language barrier and e-guidance availability in the native language are the most important barriers when communicating with patients. E-guidance availability in various native languages should be considered a major priority by international medical and health organizations that are communicating with patients at the global level.info:eu-repo/semantics/publishedVersio

Performance characteristics of Lorentz accelerators

An experimental study was made of the performance of Lorentz accelerators. Such accelerators involve the application of electric and magnetic fields to accelerate flows of partially ionized gases. Propulsion efficiencies of the accelerator of up to 28% were obtained indicating the possibility of achieving even higher efficiencies with accelerators of more advanced design. Thrust efficiencies in the vicinity of 90% were achieved; and overall efficiencies of 50% were obtained for the combined performance of the plasma generator and the Lorentz accelerator. Currents up to 1000 amperes and magnetic fields up to 0.205 webers/m2 were used. The optimum magnetic field was found to be approximately 0.180 weber/m2

Epitomics: Analysis of Plasma C9 Epitope Heterogeneity in the Plasma of Lung Cancer Patients and Control Subjects

The human proteome is more complex than the genetic code predicts it to be. Epitomics, or protein epitome profiling, is a tool for understanding sub-protein level variation. With the ultimate goal to explore C9 proteoforms and their relevance to lung cancer, here we report plasma C9 epitope-associated molecular heterogeneity in plasma samples of lung cancer patients and control subjects. We show three C9 epitopes (BSI0449, BSI0581, BSI0639) with markedly different association with lung cancer (“unaltered”, “upregulated” and “downregulated”). In order to exclude confounding effects, we show first that the three epitope-defining mAbs recognize C9 in purified form and in the natural context, in the human plasma. Then, we present data demonstrating the lack of major epitope interdependence or overlap. The next experiments represent a quest toward the understanding of the molecular basis of apparent disparate association with lung cancer. Using immunochemistry, SDS PAGE and LC-MS/MS technologies, we demonstrate that epitope-specific immunoprecipitates of plasma C9 seem identical regarding peptide sequence. However, we found epitope-specific posttranslational modification and coprecipitated protein composition differences with respect to control and lung cancer plasma. Epitope profiling enabled the classification of hypothetical C9 proteoforms through differential association with lung cancer

Epitomics: Analysis of Plasma C9 Epitope Heterogeneity in the Plasma of Lung Cancer Patients and Control Subjects

The human proteome is more complex than the genetic code predicts it to be. Epitomics, or protein epitome profiling, is a tool for understanding sub-protein level variation. With the ultimate goal to explore C9 proteoforms and their relevance to lung cancer, here we report plasma C9 epitope-associated molecular heterogeneity in plasma samples of lung cancer patients and control subjects. We show three C9 epitopes (BSI0449, BSI0581, BSI0639) with markedly different association with lung cancer (“unaltered”, “upregulated” and “downregulated”). In order to exclude confounding effects, we show first that the three epitope-defining mAbs recognize C9 in purified form and in the natural context, in the human plasma. Then, we present data demonstrating the lack of major epitope interdependence or overlap. The next experiments represent a quest toward the understanding of the molecular basis of apparent disparate association with lung cancer. Using immunochemistry, SDS PAGE and LC-MS/MS technologies, we demonstrate that epitope-specific immunoprecipitates of plasma C9 seem identical regarding peptide sequence. However, we found epitope-specific posttranslational modification and coprecipitated protein composition differences with respect to control and lung cancer plasma. Epitope profiling enabled the classification of hypothetical C9 proteoforms through differential association with lung cancer